Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead
Some of Amgen’s key businesses are drawing concerns as competition looms.
Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watche...
Continue Reading →
